CFDE Data Portal | Search LOC105379301

	Label	Description
	LOC105379301 Gene (Entity type)	ENSG00000254242 - uncharacterized LOC105379301
	GSE119369 H10 inhibition 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE218060 decitabine T cell 7 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE81796 enzalutamide LNCaP C4-2 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 3 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE208350 H-7 Huh-7 JHH-7 0 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE119369 H10 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE225900 HSDL2 knockdown 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

LOC105379301

ENSG00000254242 - uncharacterized LOC105379301

GSE119369 H10 inhibition 1 v 5 human up

A Gene Set from LINCS

GSE56010 adenosine 4 v 1 human dn

A Gene Set from LINCS

GSE261563 CX-5461 3 v 1 human dn

A Gene Set from LINCS

GSE218060 decitabine T cell 7 v 0 human dn

A Gene Set from LINCS

GSE81796 enzalutamide LNCaP C4-2 0 v 1 human up

A Gene Set from LINCS

GSE216043 cisplatin 3 v 0 human dn

A Gene Set from LINCS

GSE208350 H-7 Huh-7 JHH-7 0 v 7 human dn

A Gene Set from LINCS

GSE119369 H10 inhibition 3 v 5 human up

A Gene Set from LINCS

GSE225900 HSDL2 knockdown 1 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.